Seres Therapeutics (MCRB) EPS (Basic) (2014 - 2026)

Seres Therapeutics (MCRB) posted EPS (Basic) of -$2.67 for Q1 2026, down 114.56% sequentially from $18.32 in Q3 2024.

Seres Therapeutics (MCRB) EPS (Basic) (2014 - 2026) Analysis & Trends

Seres Therapeutics has reported EPS (Basic) for 12 years, with the latest figure at -$2.67 in Q1 2026.

Quarterly EPS (Basic) changed N/A year-over-year to -$2.67 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.67 (down 121.71% YoY) and the FY2024 annual result came in at $16.2, up 35.73% from the prior year.
EPS (Basic) slipped to -$2.67 in Q1 2026 per MCRB's latest filing, from $18.32 in the prior quarter.
Over five years, EPS (Basic) peaked at $18.32 in Q3 2024 and troughed at -$2688.9 in Q3 2022.
A 4-year average of -$242.3 and a median of -$3.5 in 2024 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2022 and 2024: EPS (Basic) tumbled 376.21% in 2022, then jumped 1818.1% in 2024.
Over 4 years, EPS (Basic) stood at -$11.17 in 2022, then surged by 90.86% to -$1.02 in 2023, then surged by 1895.11% to $18.32 in 2024, then plunged by 114.56% to -$2.67 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered -$2.67, $18.32, and -$4.34 for Q1 2026, Q3 2024, and Q2 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	12.62
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	7.59
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-1.96
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	2.12
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.23
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.06
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.18
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-0.72
10	Seres Therapeutics	43.82 Mn	43.82 Mn	-	-2.17

Download Data